Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies, and antibody binding fragments thereof, capable of being used for therapeutic, diagnostic, detection and cell purification purposes. An exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to surface antigen expressed on multiple myeloma cells and on ovarian cancer cells.
1. A method of killing or inhibiting the growth of myeloma tumor cells or ovarian cancer tumor cells comprising administering to an individual in need thereof a composition comprising a monoclonal antibody, deposited under ATCC designation number PTA-450, or antigen binding fragment thereof, under conditions sufficient for binding of the monoclonal antibody, or antigen binding fragment thereof, to said tumor cells, thereby inducing growth inhibition or killing of said tumor cells.
2. A method of killing or inhibiting the growth of myeloma tumor cells or ovarian cancer tumor cells comprising administering to an individual in need thereof a composition comprising a monoclonal antibody, deposited under ATCC designation number PTA-450, or antigen binding fragment thereof, wherein said monoclonal antibody, or antigen binding fragment thereof, is conjugated with a cytotoxic moiety, under conditions sufficient for binding of said monoclonal antibody, or antigen binding fragment thereof, to said tumor cells, thereby inducing killing or growth inhibition of said tumor cells.
3. The method according to claim 2 wherein said cytotoxic moiety is a chemotherapeutic agent, a photo-activated toxin, or a radioactive agent.
4. A method for killing or inhibiting the growth of myeloma cells in a isolated cellular sample comprising exposing said cellular sample to a monoclonal antibody, deposited under ATCC designation number PTA-450, or antigen binding fragment thereof, conjugated with a cytotoxic moiety under conditions sufficient for the binding of said monoclonal antibody or antigen binding fragment thereof to said myeloma cells causing killing or growth inhibition of said mycloma cells.
5. The method of claim 4 wherein said cytotoxic moiety is a chemotherapeutic agent, a photo-activated toxin or a radioactive agent.
6. The method of claim 4 wherein said cellular sample comprises bone marrow cells.
7. The method of claim 6 wherein said bone marrow cells from which said mycloma cells are removed are used for transplant.
8. The method of claim 7 wherein said transplant is an autologous bone marrow transplant.
9. A method of killing or inhibiting the growth of myeloma tumor cells or ovarian cancer tumor cells comprising
contacting said tumor cells with a composition comprising a monoclonal antibody, deposited under ATCC designation number PTA-450, or antigen binding fragment thereof, wider conditions sufficient for binding of said monoclonal antibody, or antigen binding fragment thereof, to said tumor cells, thereby killing or inhibition the growth of said tumor cells.
10. The method of claim 9 , wherein said monoclonal antibody, or antigen binding fragment thereof, is conjugated with a cytotoxic moiety.
11. The method of claim 10 wherein said cytotoxic moiety is a chemotherapeutic agent, a photo-activated toxin, or a radioactive agent.
12. The method of claim 1 , wherein said monoclonal antibody, or antigen binding fragment thereof, is administered together with a physiologically acceptable carrier or diluent.
13. The method of claim 9 , wherein said antigen binding fragment is selected from the group consisting of F(ab′)2, Fab′, Fv, Fd′ and Fd.
14. The method of claim 2 , wherein said monoclonal antibody, or binding fragment thereof, is administered together with a physiologically acceptable carrier or diluent.
15. The method of claim 2 , wherein said binding fragment is selected from the group consisting of F(ab′) 2 , Fab′, Fv, Fd′ and Fd.
16. A method of killing or inhibiting the growth of myeloma tumor cells or ovarian cancer tumor cells comprising
contacting said tumor cells with a composition comprising a monoclonal antibody, or antigen binding fragment thereof, under conditions sufficient for the binding of said monoclonal antibody, or binding fragment thereof, to said tumor cells, thereby inducing killing or growth inhibition of said tumor cells,
wherein said monoclonal antibody is a monoclonal antibody deposited under ATCC designation number PTA-450, wherein said monoclonal antibody, or antigen binding fragment thereof, is inimunoreactive with cell surface membranes of human mycloma cells or human ovarian cancer cells.
17. The method of claim 16 , wherein said monoclonal antibody, or antigen binding fragment thereof, is not immunoreactive with cell surface membranes of human peripheral blood mononuclear cells, human B cells, neuroblastoma cells, human B cell myelogenic leukemia cells, breast cancer cells, prostate cancer cells, or cervical cancer cells.
18. The method of claim 16 , wherein said monoclonal antibody, or antigen binding fragment thereof, is conjugated with a cytotoxic moiety.
19. The method of claim 18 wherein said cytotoxic moiety is a chemotherapeutic agent, a photo-activated toxin, or a radioactive agent.
20. The method of claim 16 , wherein said antigen binding fragment is selected from the group consisting of F(ab′) 2 , Fab′, Fv, Fd′ and Fd.
21. The method of claim 1 , wherein said monoclonal antibody is inununoreactive with cell surface membranes of both human myeloma cells and ovarian cancer cells and is not immunoreactive with cell surface membranes of human peripheral blood mononuclear cells, human B cells, neuroblastoma cells, human B cell myclogenic leukemia cells, breast cancer cells, prostate cancer cells, or cervical cancer cells.
22. The method of claim 2 , wherein said monoclonal antibody is immunoreactive with cell surface membranes of both human myeloma cells and ovarian cancer cells and is not immunoreactive with cell surface membranes of human peripheral blood mononuclear cells, human B cells, neuroblastoma cells, human B cell myelogenic leukemia cells, breast cancer cells, prostate cancer cells, or cervical cancer cells.
23. The method of claim 4 , wherein said monoclonal antibody is immunoreactive with cell surface membranes of both human mycloma cells and ovarian cancer cells and is not immunoreactive with cell surface membranes of human peripheral blood mononuclear cells, human B cells, neuroblastoma cells, human B cell myclogenic leukemia cells, breast cancer cells, prostate cancer cells, or cervical cancer cells.
24. The method of claim 1 , wherein said antigen binding fragment is selected from the group consisting of F(ab′) 2 , Fab′, Fv, Fd′ and Fd.
25. The method of claim 4 , wherein said antigen binding fragment is selected from the group consisting of F(ab′) 2 , Fab′, Fv, Fd′ and Fd.